Ascletis Pharma Inc. (01672) submitted its monthly return as of 31 October 2025, confirming that the total authorised share capital stands at 7,000,000,000 ordinary shares with a par value of USD 0.0001, amounting to USD 700,000 in total.

The number of issued shares (excluding treasury shares) decreased from 993,174,320 to 992,074,320 during the period, while treasury shares increased from 5,784,210 to 6,884,210. Following these changes, the total number of issued shares remains at 998,958,530. Repurchases of 1,100,000 shares were made, which now sit in treasury. Additionally, some previously repurchased shares totaling 960,000 remain pending cancellation. No new shares were issued pursuant to the share option schemes, although 240,000 previously allocated options were canceled under the scheme approved on 6 June 2019.